Thrombin hypothesis: The TIMI 9B and GUSTO IIB trials have successfully disproven/proven the thrombin hypothesis

Journal of Thrombosis and Thrombolysis

Volumn 4, Issue 3-4, 1997, Pages 317-319

  White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

Acute myocardial infarction; Heparin; Hirudin; Unstable angina

Indexed keywords

HEPARIN; HIRUDIN; THROMBIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; SHORT SURVEY; ST SEGMENT ELEVATION;

EID: 0030765673     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008828812299     Document Type: Short Survey

References (17)

1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
2. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I Trial. Circulation 1996;93:870-878.
3. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90:1624-1630.
4. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996;94:911-921.
5. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
7. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-1220.
8. Heras M, Chesebro JH, Penny WJ, et al. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: Heparin versus recombinant hirudin, a specific-thrombin inhibitor. Circulation 1989;79:657-665.
9. Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989;55:635-643.
10. Lee CD, Mann KG. Activation/inactivation of human coagulation factor V by plasmin. Blood 1989;73:185-190.
11. Jang IK, Gold HK, Ziskind AA, et al. Prevention of plateletrich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-225.
12. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, et al. Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. Circulation 1994;90:2658-2665.
13. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
14. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol 1994;23:993-1003.
15. Zoldhelyi P, Janssens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO 2A Investigators. Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995; 92(Suppl I):I-740 (abstr).
16. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039-1047.
17. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.